Expression of major vault protein gene in osteosarcoma patients
Cristiane Arruda Dalla‐Torre(Support group for adolescents and children with cancer), Maria Zieleńska(University of Toronto), Antônio Sérgio Petrilli(Support group for adolescents and children with cancer), Sílvia Regina Caminada de Toledo(Support group for adolescents and children with cancer), Maisa Yoshimoto(University of Alberta), Jeremy A. Squire(Universidade de São Paulo), Joyce Anderson Duffles Andrade(Associação Paulista de Medicina), Susan Chilton‐MacNeill(Hospital for Sick Children)
Cited by 13
Related Papers
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|353
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
|British Journal of Cancer|2007|294
Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
|Current Genomics|2008|293
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
|Modern Pathology|2008|278